文献速递眼底病与葡萄膜炎

阿柏西普治疗新生血管性年龄相关性黄斑变性不同亚型的临床结局

CLINICAL OUTCOMES OF DIFFERENT SUBTYPES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DURING AFLIBERCEPT TREATMENT.
PubMed 文献 · Retina · 2021-01-01

这项前瞻性研究纳入44例未经治疗的新生血管性年龄相关性黄斑变性患者(PCV、hCNV、PED、RAP四个亚型),接受阿柏西普单药玻璃体腔注射并随访12个月。结果显示所有亚型均获得解剖学改善和视力稳定,84%患眼视力提高或稳定,hCNV平均视力增益最大,PED在12个月时萎缩面积最大。

要点

  • 阿柏西普单药治疗12个月,84%患眼视力提高或稳定(±5字母以内)。
  • hCNV亚型平均视力增益最大,所有亚型均显示解剖学改善。
  • PED亚型在12个月时萎缩面积最大,但总体萎缩面积变化无统计学意义。

核心结论

  • 所有新生血管性年龄相关性黄斑变性亚型在阿柏西普玻璃体腔治疗期间均显示解剖学改善和视功能稳定。

研究设计与样本

  • 前瞻性研究纳入44例44眼未经治疗的新生血管性年龄相关性黄斑变性患者,分为PCV(n=12)、hCNV(n=12)、PED(n=11)和RAP(n=9)四个亚型,随访12个月。

主要发现

  • 12个月时84%患眼(37/44)视力提高或稳定(较基线±5字母以内),hCNV平均视力增益最大。
  • PCV平均中心视网膜厚度从523±251 µm降至310±91 µm,hCNV从497±171 µm降至323±75 µm,RAP从573±132 µm降至357±173 µm,PED从541±158 µm降至422±150 µm。
  • 平均萎缩面积从基线2.0±3.6 mm²增至12个月4.6±8.6 mm²(平均差值-0.8,95%CI -8.5至7.0,P=0.8),PED患者12个月时萎缩面积最大。

临床怎么用

  • 阿柏西普单药治疗可使不同亚型新生血管性年龄相关性黄斑变性获得解剖学改善和视力稳定,hCNV视力增益可能更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To prospectively evaluate the outcomes of different subtypes of neovascular age-related macular degeneration during intravitreal aflibercept monotherapy. METHODS: Forty-four eyes of 44 patients with treatment-naïve polypoidal choroidal vasculopathy (PCV, n = 12), hemorrhagic choroidal neovascularization (hCNV, n = 12), pigment epithelium detachment (PED, n = 11), or retinal angiomatous proliferation (RAP, n = 9) were included and followed for 12 months. All patients received intravitreal aflibercept monotherapy. RESULTS: Mean visual acuity at baseline in PCV was 67 ± 16 Early Treatment Diabetic Retinopathy Study letters (20/50 Snellen equivalent), in hCNV 55 ± 21 (20/80), in RAP lesions 64 ± 11 (20/50), and in PED 74 ± 7 (20/32). At Month 12, visual acuity in PCV was 66 ± 16 (20/50), in hCNV 69 ± 17 (20/40), in RAP 68 ± 12 (20/50), and in PED 69 ± 18 (20/40). At the 12-month follow-up, visual acuity improved or was stable (±5 letters from baseline) in 84% of eyes (37/44 patients), with hCNV showing the greatest mean visual acuity gain. Mean central retinal thickness in patients with PCV was 523 ± 251 µm, in hCNV 497 ± 171, in RAP lesions 573 ± 132, and in PED 541 ± 158 and decreased to 310 ± 91 µm in PCV, 323 ± 75 µm in hCNV, 357 ± 173 µm in RAP lesions, and 422 ± 150 µm in PED. The mean area of atrophy increased from 2.0 ± 3.6 mm2 at baseline to 4.6 ± 8.6 mm2 at Month 12 (mean difference [95% confidence interval] -0.8 [-8.5 to 7.0], P = 0.8), with the greatest atrophy in patients with PED at Month 12. CONCLUSION: All subtypes of neovascular age-related macular degeneration showed anatomical improvement and stabilization of visual function during intravitreal treatment.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Rezar-Dreindl S, Eibenberger K, Buehl W, et al. CLINICAL OUTCOMES OF DIFFERENT SUBTYPES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DURING AFLIBERCEPT TREATMENT. Retina. 2021. PMID: 32091488. doi:10.1097/IAE.0000000000002786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。